This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Editorial

. 2021 Sep;31(9):801-802.

doi: 10.1016/j.nmd.2021.09.003.

Tamoxifen in Duchenne muscular dystrophy - promising first results

Urs Rüegg¹

Affiliations

PMID: 34635289
DOI: 10.1016/j.nmd.2021.09.003

Editorial

Tamoxifen in Duchenne muscular dystrophy - promising first results

Urs Rüegg. Neuromuscul Disord. 2021 Sep.

. 2021 Sep;31(9):801-802.

doi: 10.1016/j.nmd.2021.09.003.

Author

Urs Rüegg¹

Affiliation

¹ Emeritus Professor of Pharmacology, Pharmaceutical Sciences, University of Geneva, 1211 Geneva 4, Switzerland. Electronic address: urs.ruegg@unige.ch.

PMID: 34635289
DOI: 10.1016/j.nmd.2021.09.003

No abstract available

PubMed Disclaimer

Comment on

Safety and clinical outcome of tamoxifen in Duchenne muscular dystrophy.
Tsabari R, Simchovitz E, Lavi E, Eliav O, Avrahami R, Ben-Sasson S, Dor T. Tsabari R, et al. Neuromuscul Disord. 2021 Sep;31(9):803-813. doi: 10.1016/j.nmd.2021.05.005. Epub 2021 Jun 5. Neuromuscul Disord. 2021. PMID: 34304968 Clinical Trial.

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions

Substances

Actions

LinkOut - more resources

Full Text Sources
- ClinicalKey
- Elsevier Science
Other Literature Sources
- The Lens - Patent Citations Database